WO2007091719A1 - Thérapie concomitante par anticorps anti-gpvi et son utilisation médicinale novatrice - Google Patents

Thérapie concomitante par anticorps anti-gpvi et son utilisation médicinale novatrice Download PDF

Info

Publication number
WO2007091719A1
WO2007091719A1 PCT/JP2007/052546 JP2007052546W WO2007091719A1 WO 2007091719 A1 WO2007091719 A1 WO 2007091719A1 JP 2007052546 W JP2007052546 W JP 2007052546W WO 2007091719 A1 WO2007091719 A1 WO 2007091719A1
Authority
WO
WIPO (PCT)
Prior art keywords
gpvi
antibody
drug
collagen
platelets
Prior art date
Application number
PCT/JP2007/052546
Other languages
English (en)
Japanese (ja)
Inventor
Hiroshi Takayama
Yoshitaka Hosaka
Yukiko Yatagai
Tetsushi Kawahara
Original Assignee
Mochida Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharmaceutical Co., Ltd. filed Critical Mochida Pharmaceutical Co., Ltd.
Priority to JP2007557914A priority Critical patent/JPWO2007091719A1/ja
Publication of WO2007091719A1 publication Critical patent/WO2007091719A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention permet d'obtenir : un médicament pour prévenir ou traiter une maladie en rapport avec les plaquettes ou le système de coagulation sanguine, contenant, comme principes actifs, un agent antiplaquettaire qui inhibe spécifiquement la coagulation des plaquettes induite par le collagène et/ou un agent antithrombotique, et visant à utiliser ces agents de façon concomitante, et ainsi de suite ; un agent prophylactique/un remède pour une maladie associée à une lésion de cellules endothéliales vasculaires, caractérisé en ce qu'il comprend, comme principe actif, une substance qui inhibe spécifiquement la coagulation par le collagène ; et un inhibiteur pour une lésion de cellules endothéliales vasculaires ou une lésion d'organe qui comprend, comme principe actif, une substance qui inhibe spécifiquement la coagulation de plaquettes induite par le collagène. Ainsi, il devient possible d'obtenir : une thérapie pour une maladie en rapport avec les plaquettes ou le système de coagulation sanguine, en utilisant de façon concomitante un agent antiplaquettaire qui inhibe spécifiquement la coagulation de plaquettes induite par le collagène avec un agent antithrombotique ; un médicament, une préparation ou une composition médicinale pour une utilisation concomitante ; et une utilisation novatrice d'anticorps anti-GPVI comme agent prophylactique/remède pour une maladie associée à une lésion de cellules endothéliales vasculaires.
PCT/JP2007/052546 2006-02-07 2007-02-07 Thérapie concomitante par anticorps anti-gpvi et son utilisation médicinale novatrice WO2007091719A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007557914A JPWO2007091719A1 (ja) 2006-02-07 2007-02-07 抗ｇｐｖｉ抗体の併用療法及び新規医薬用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2006-030306 2006-02-07
JP2006030306 2006-02-07
JP2006152436 2006-05-31
JP2006-152436 2006-05-31

Publications (1)

Publication Number Publication Date
WO2007091719A1 true WO2007091719A1 (fr) 2007-08-16

Family

ID=38345305

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/052546 WO2007091719A1 (fr) 2006-02-07 2007-02-07 Thérapie concomitante par anticorps anti-gpvi et son utilisation médicinale novatrice

Country Status (2)

Country Link
JP (1) JPWO2007091719A1 (fr)
WO (1) WO2007091719A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009123210A1 (fr) * 2008-04-01 2009-10-08 アステラス製薬株式会社 Agent préventif et/ou remède pour maladies vasculaires
WO2010075861A3 (fr) * 2008-12-30 2010-10-07 Thrombologic Aps Détection de patients dans un état critique présentant un risque accru de développer une défaillance viscérale et composés pour les traiter
EP2336188A1 (fr) * 2009-12-18 2011-06-22 Sanofi-Aventis Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations
EP2397495A1 (fr) * 2010-06-21 2011-12-21 Sanofi Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations
WO2011073954A3 (fr) * 2009-12-18 2012-03-08 Sanofi-Aventis Nouveaux anticorps antagonistes et leurs fragments fab dirigés contre gpvi, et utilisations de ceux-ci
JP2022518363A (ja) * 2018-12-31 2022-03-15 ダイノナ Ｉｃａｍ－１に特異的に結合する抗体およびその用途
WO2022136457A1 (fr) * 2020-12-24 2022-06-30 The University Of Birmingham Nanocorps de glycoprotéine vi

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002363100A (ja) * 2001-01-23 2002-12-18 Bernhard Nieswandt 血栓性疾患防止のための医薬品
WO2006061650A2 (fr) * 2004-12-10 2006-06-15 Trigen Gmbh Procedes, produits et utilisations relatifs a des plaquettes et/ou la vasculature
WO2006117910A1 (fr) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Anticorps monoclonal contre la glycoproteine vi de la membrane de la plaquette
WO2006118350A1 (fr) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Anticorps monoclonal anti-glycoprotéine vi de membrane plaquettaire

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002363100A (ja) * 2001-01-23 2002-12-18 Bernhard Nieswandt 血栓性疾患防止のための医薬品
WO2006061650A2 (fr) * 2004-12-10 2006-06-15 Trigen Gmbh Procedes, produits et utilisations relatifs a des plaquettes et/ou la vasculature
WO2006117910A1 (fr) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Anticorps monoclonal contre la glycoproteine vi de la membrane de la plaquette
WO2006118350A1 (fr) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Anticorps monoclonal anti-glycoprotéine vi de membrane plaquettaire

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CABEZA N. ET AL.: "Surface expression of collagen receptor Fc receptor-gamma/glycoprotein VI is enhanced on platelets in type 2 diabetes and mediates release of CD40 ligand and activation of endothelial cells", DIABETES, vol. 53, no. 8, 2004, pages 2117 - 2121, XP003015888 *
GRUNER S. ET AL.: "Anti-glycoprotein VI treatment severely compromises hmeostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy", CIRCULATION, vol. 110, no. 18, 2004, pages 2946 - 2951 *
LECUT C. ET AL.: "Principal role of glycoprotein VI in alpha2beta1 and alphaIIbbeta3 activation during collagen-induced thrombus formation", ARTERIOSCLER. THROMB. VASC. BIOL., vol. 24, no. 9, 2004, pages 1727 - 1733 *
MATSUYAMA S.: "A CLINICAL STUDY OF THE PATHOGENESIS AND THERAPY OF RETINAL VENOUS OCCLUSION", FOLIA OPHTHALMOLOGICA JAPONICA, vol. 41, no. 10, 1990, pages 1883 - 1890, XP003015891 *
NAKAMURA T. ET AL.: "Platelet adhesion to native type I collagen fibrils. Role of GPVI in divalent cation-dependent and -independent adhesion and thromboxane A2 generation", J. BIOL. CHEM., vol. 273, no. 8, 1998, pages 4338 - 4344 *
NOMURA T.: "Ko Kessen, Kesshoban GPIIb/IIIa Juyotai Sogaizai", IGAKU NO AYUMI, vol. 210, no. 6, 2004, pages 623 - 629 *
SAGRIPANTI A. ET AL.: "Iloprost in the treatment of thrombotic microangiopathy: report of thirteen cases", BIOMED. PHARMACOTHER., vol. 50, no. 8, 1996, pages 350 - 356, XP003015889 *
YOSHIKAWA T. ET AL.: "Effect of cilostazol and warfarin on the patency after placement of PTFE-covered spiral Z-stent in vena cava in dogs", JAPANESE JOURNAL OF PHARMACOLOGY, vol. 71, no. SUPPL., 1996, pages 148P, XP003015890 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5589838B2 (ja) * 2008-04-01 2014-09-17 アステラス製薬株式会社 血管性疾患の予防剤及び／又は治療剤
WO2009123210A1 (fr) * 2008-04-01 2009-10-08 アステラス製薬株式会社 Agent préventif et/ou remède pour maladies vasculaires
JPWO2009123210A1 (ja) * 2008-04-01 2011-07-28 アステラス製薬株式会社 血管性疾患の予防剤及び／又は治療剤
WO2010075861A3 (fr) * 2008-12-30 2010-10-07 Thrombologic Aps Détection de patients dans un état critique présentant un risque accru de développer une défaillance viscérale et composés pour les traiter
US9381243B2 (en) 2008-12-30 2016-07-05 Rigshospitalet Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
US8877710B2 (en) 2008-12-30 2014-11-04 Righospitalet Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
US9441040B2 (en) 2009-12-18 2016-09-13 Sanofi Antagonist antibodies and their fab fragments against GPVI and uses thereof
US8852593B2 (en) 2009-12-18 2014-10-07 Sanofi Antagonist antibodies and their fab fragments against GPVI and uses thereof
WO2011073954A3 (fr) * 2009-12-18 2012-03-08 Sanofi-Aventis Nouveaux anticorps antagonistes et leurs fragments fab dirigés contre gpvi, et utilisations de ceux-ci
EP2933269A1 (fr) * 2009-12-18 2015-10-21 Sanofi Nouveaux anticorps antagonistes et leurs fragments fab contre le gpvi et utilisation de ceux-ci
AU2010331807B2 (en) * 2009-12-18 2016-08-04 Sanofi Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
EP2336188A1 (fr) * 2009-12-18 2011-06-22 Sanofi-Aventis Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations
EP2397495A1 (fr) * 2010-06-21 2011-12-21 Sanofi Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations
JP2022518363A (ja) * 2018-12-31 2022-03-15 ダイノナ Ｉｃａｍ－１に特異的に結合する抗体およびその用途
JP7308957B2 (ja) 2018-12-31 2023-07-14 クンホ、エイチティー、インコーポレイテッド Ｉｃａｍ－１に特異的に結合する抗体およびその用途
WO2022136457A1 (fr) * 2020-12-24 2022-06-30 The University Of Birmingham Nanocorps de glycoprotéine vi

Also Published As

Publication number Publication date
JPWO2007091719A1 (ja) 2009-07-02

Similar Documents

Publication Publication Date Title
AU2019201075B2 (en) Treatment of cancer using humanized anti-EGFRVIII chimeric antigen receptor
US9926369B2 (en) Methods for treating hepatocellular cancer by administering an anti-Ang-2 antibody
US20170306050A1 (en) Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
AU2013203619B2 (en) Antibodies to matrix metalloproteinase 9
JP7141130B2 (ja) Ｃ５ａ阻害剤としての６－５融合環
WO2007091719A1 (fr) Thérapie concomitante par anticorps anti-gpvi et son utilisation médicinale novatrice
KR20180086502A (ko) 항-lag3 항체 및 항원-결합 단편
TW201726730A (zh) 抗ｌａｇ３抗體及其用途
TWI613215B (zh) 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
KR102586710B1 (ko) C5a 억제제로서의 5-5 융합 고리
BRPI0922885B1 (pt) Anticorpo humano que se liga especificamente à próproteina convertase subtilisina/kexina tipo 9 (hpcsk9) humana, molécula de ácido nucleico isolada, vetor de expressão, método para produzir o referido anticorpo e composição farmacêutica
AU2010276544A1 (en) High affinity human antibodies to human angiopoietin-2
TWI771372B (zh) Wnt抑制劑與抗-pd-1抗體分子組合之給藥方案
US9371379B2 (en) Methods for treating malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
US8197811B2 (en) Methods of use of sialoadhesin factor-2 antibodies
JP2016147910A (ja) 同種移植片の生存を長期化するための抗ｃｄ２００抗体の使用
US10106601B2 (en) Inhibition of PLGF to treat philadelphia chromosome positive leukemia
US20150366867A1 (en) Methods of treating atherosclerosis or myeloproliferative neoplasms by administering a lyn kinase activator
EP3286221A1 (fr) Méthodes et compositions pharmaceutiques pour le traitement de maladies médiées par th17
EP4232070A1 (fr) Procédés d'induction de la mobilisation de cellules souches
EP3490675A1 (fr) Lymphocytes t gamma delta utilisés comme cible pour le traitement de tumeurs solides
WO2012110843A1 (fr) Méthodes et compositions pharmaceutiques pour promouvoir la fibrinolyse et la thrombolyse
JP2023549835A (ja) がんを治療する材料及び方法
JP2023551894A (ja) 抗ｃｄ３０抗体－薬物コンジュゲートを使用した免疫応答の調節
WO2023070097A2 (fr) Anticorps se liant au domaine a2 du facteur xi et leurs procédés d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2007557914

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07714126

Country of ref document: EP

Kind code of ref document: A1